Item 1.01 Entry into a Material Definitive Agreement.
On
The Agreement contains certain customary representations, warranties and
covenants of the parties, and the acquisition of the Property is expected to
close in
There can be no assurances that the acquisition will be completed on the expected timeline, on the expected terms or at all.
The foregoing description of the Agreement is qualified in its entirety by the text of the Agreement filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 2.02. Results of Operations and Financial Condition.
On
The information contained in Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and other
federal securities laws, including, without limitation, statements regarding the
completion of the pending acquisition. Forward-looking statements, which are
based on certain assumptions and describe future plans, strategies and
expectations of the Company, are generally identifiable by use of the words
"anticipate," "believe," "estimate," "expect," "intend," "may," "plan,"
"predict," "project," "target," "potential," "likely," "will," "would," "could,"
"should," "continue," and similar expressions. The Company's ability to predict
results or the actual effect of future plans or strategies is inherently
uncertain and may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the sufficiency
of cash resources and need for additional financing and such other important
factors as are set forth under the caption "Risk Factors" in Krystal's annual
and quarterly reports on file with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 10.1 Purchase and Sale Agreement, datedJanuary 29, 2021 , by and betweenKrystal Biotech, Inc. andNorthfield I, LLC . 104 Cover Page Interactive Data file (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source